Polypodium leucotomos extract use to prevent and reduce the risk of infectious diseases in high performance athletes

Infection and Drug Resistance

Volumn 5, Issue 1, 2012, Pages 149-153

  Solivellas, Bartolomé Marí ^a   Martín, Teo Cabanes ^b  

^a Sports Medicine Service   (Spain)

^b Mallorca Regional Government   (Spain)

Author keywords

Immunological stress; Polypodium leucotomos extract; Recurrent infections

Indexed keywords

POLYPODIUM LEUCOTOMOS EXTRACT;

ABSCESS; ACUTE GASTROENTERITIS; ADULT; ARTICLE; ATHLETE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVENING DOSAGE; FEMALE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OTITIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PHARYNGITIS; RELAPSE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK REDUCTION;

EID: 84872907173     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nieman DC. Upper respiratory tract infections and exercise. Thorax. 1995;50(12):1229-1231.
2. Nieman DC. Exercise, infection, and immunity. Int J Sports Med. 1994; 15(Suppl 3):S131-S141.
3. Nieman DC. Risk of upper respiratory tract infection in athletes: an epidemiologic and immunologic perspective. J Athl Train. 1997;32(4): 344-349.
4. Nieman DC, Pedersen BK. Exercise and immune function. Recent developments. Sports Med. 1999;27(2):73-80.
5. Kakanis M W, Peake J, Brenu EW, et al. The open window of susceptibility to infection after acute exercise in healthy young male elite athletes. Exerc Immunol Rev. 2010;16:119-137.
6. Nieman DC. Current perspective on exercise immunology. Curr Sports Med Rep. 2003;2(5):239-242.
7. Moreira A, Delgado L, Moreira P, Haahtela T. Does exercise increase the risk of upper respiratory tract infections? Br Med Bull. 2009;90: 111-131.
8. Nieman DC. Immunonutrition support for athletes. Nutr Rev. 2008; 66(6):310-320.
9. Akerstrom TC, Pedersen BK. Strategies to enhance immune function for marathon runners: what can be done? Sports Med. 2007;37(4-5): 416-419.
10. Nieman DC. Marathon training and immune function. Sports Med. 2007;37(4-5):412-415.
11. Nielsen HG, Lyberg T. Long-distance running modulates the expression of leucocyte and endothelial adhesion molecules. Scand J Immunol. 2004;60(4):356-362.
12. Moreira A, Kekkonen RA, Delgado L, Fonseca J, Korpela R, Haahtela T. Nutritional modulation of exercise-induced immunodepression in athletes: a systematic review and meta-analysis. Eur J Clin Nutr. 2007;61(4):443-460.
13. Walsh N P, Gleeson M, Shephard RJ, et al. Position statement. Part one: immune function and exercise. Exerc Immunol Rev. 2011;17: 6-63.
14. Walsh N P, Gleeson M, Pyne DB, et al. Position statement. Part two: maintaining immune health. Exerc Immunol Rev. 2011;17:64-103.
15. Boff El, Amari E. Upper respiratory tract infections and sports. Rev Med Suisse. 2010;6(258):1499-1503. French.
16. Romeo J, Warnberg J, Pozo T, Marcos A. Physical activity, immunity and infection. Proc Nutr Soc. 2010;69(3):390-399.
17. Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med. 2001;163(7):1578-1583.
18. Dias R, Frollini AB, Brunelli DT, et al. Immune parameters, symptoms of upper respiratory tract infections, and training-load indicators in volleyball athletes. Int J Gen Med. 2011;4:837-844.
19. Cordova A, Martin J F, Reyes E, Alvarez-Mon M. Protection against muscle damage in competitive sports players: the effect of the immunomodulator AM3. J Sports Sci. 2004;22(9):827-833.
20. Cordova A, Monserrat J, Villa G, Reyes E, Soto MA. Effects of AM3 (Inmunoferon) on increased serum concentrations of interleukin-6 and tumour necrosis factor receptors I and II in cyclists. J Sports Sci. 2006;24(6):565-573.
21. Sempere JM, Rodrigo C, Campos A, Villalba JF, Diaz J. Effects of anapsos (Polypodium leucotomos extract) on in vitro production of cytokines. Br J Clin Pharmacol. 1997;43(1):85-89.
22. Bernd A, Ramirez-Bosca A, Huber H, et al. In vitro studies on the immunomodulating effects of Polypodium leucotomos extract on human leucocyte fractions. Arzneimittelforschung. 1995;45(2):901-904.
23. Navarro-Blasco FJ, Sempere JM. Modifcation of the infammatory activity of psoriatic arthritis in patients treated with extract of Polypodium leucotomos (anapsos). Br J Rheumatol. 1998;37(8):912-917.
24. Sempere JM, Campos A, Velasco I, et al. Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002;46(2):185-190.
25. Carreno MM, De Castro P. Immune Phenotype and Polypodium leucotomos treatment in patients with MS. Neurologia. 1994;10:509.
26. De Castro P, Carreno MM, Sempere JM. Effects of anapsos in the treatment of multiple sclerosis patients. J Neurol. 1999;246(1):111.
27. Sempere JM, Campos A, Rodrigo C, Velasco MF, Carrion MA. Induction of T lymphocytes and NK cells by anapsos. Inmunologia. 1999;18(Suppl 1).
28. Martinez FO, Rodriquez JH. Treatment of adult non-bacterial tonsillitis with anapsos. Elsevier Doyma; 2004.
29. Martinez FO. 2007 Monitoring in patients with non-bacterial tonsillitis treated anapso. Elsevier Doyma; 2007.
30. Ordonez JE. Anapsos utilization in mollusc injuries. Elsevier Doyma; 2008.
31. Ramirez A, Martinez A, Gonzalez M, Gosalbez J, Ballester J, Campos SJ. Reduced consumption of topical steroids in patients with atopic dermatitis treated with anapsos. Elsevier Doyma; 2008.
32. Del Prado ME. Treatment of common warts with anapsos recaltritantes. Elsevier Doyma; 2009.
33. Arruti I, Rodriguez P, Casall P. Rating anapsos activity in children with pharyngitis reduction mediantes number of tonsillectomies. Elsevier Doyma; 2011. Spanish.
34. Aguila A, Bargues R, Saiz JM, et al. Anapsos use in the treatment of chronic recurrent tonsillitis pharyngocutaneous. ORL Aragon. 2011;14(2): 25-27. Spanish.